SF3B1 Variant in MDS Found to Identify Distinct Disease Entities
An international working group of experts in myelodysplastic syndromes proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic mutation that causes the disease. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
EU Panel OKs Glasdegib for AML & Luspatercept for MDS EU Panel OKs Glasdegib for AML & Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
First Advance in MDS for Decade: Luspatercept for Anemia First Advance in MDS for Decade: Luspatercept for Anemia
Luspatercept is now approved for use in the treatment of anemia in patients with myelodysplastic syndromes (MDS).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
FDA Approves Reblozyl (luspatercept-aamt) to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2020-- Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2020 Category: Drugs & Pharmacology Source Type: news
Chelation Beneficial in Iron-overloaded Patients at Lower Risk of Myelodysplastic Syndromes Chelation Beneficial in Iron-overloaded Patients at Lower Risk of Myelodysplastic Syndromes
Iron chelation therapy (ICT) with deferasirox led to longer event-free survival in iron-overloaded patients at low-to-intermediate risk of myelodysplastic syndrome (MDS) in a phase 2 study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Iron Chelation Therapy Treats Iron Overload in MDS
MONDAY, March 23, 2020 -- Iron chelation therapy (ICT) seems beneficial for iron-overloaded patients with low- or intermediate-1-risk myelodysplastic syndromes (MDS), according to a study published online March 24 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2020 Category: Pharmaceuticals Source Type: news
Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 29, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news
Reducing Blood Cancer Patients' Need for Transfusions
January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM). (Source: Einstein News)
Source: Einstein News - January 21, 2020 Category: Universities & Medical Training Source Type: news
Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported in the Jan. 9 New England Journal of Medicine.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Luspatercept Mitigates Anemia in Lower - Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower - risk myelodysplastic syndromes with ring sideroblasts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 9, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Jan. 8, 2020 -- For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who have been receiving regular red-cell transfusions, luspatercept reduces the severity of anemia compared with placebo, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2020 Category: Pharmaceuticals Source Type: news
Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome
A study of hematopoietic stem cell transplantation (HCT) for adults with myelodysplastic syndrome (MDS) showed that patients 65 and older had comparable outcomes to those ages 55 to 64, leading the authors to recommend that the US Centers for Medicare and Medicaid Services cover HCT.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
